以VM26为主的联合化疗方案治疗进展期胃癌的临床研究

A CLINICAL STUDY OF COMBINATION CHEMOTHERAPY MAINLY INCLUDING VM26 FOR ADVANCED GASTRIC CANCER

目的观察以VM26为主的联合化疗方案对进展期胃癌的疗效和毒副反应。方法122例进展期胃癌随机分为VLF组（VM26，甲酰四氢叶酸，5－FU）和VF组（VM26，5－FU），分别观察其疗效和毒副反应。结果VLF组CR6例，PR34例，有效率46％，VF组CR2例，PR9例，有效率31．4％，但无统计学差异；进行3～4个疗程者有效率为51．6％，高于2个疗程的38．5％，但无统计学差异；毒副反应有厌食，恶心呕吐等消化道反应和骨髓抑制等，但患者可以耐受。结论VM26对进展期胃癌有较好的疗效。

To observe the efficacy and the adverse effects of combination chemotherapy mainly includingVM26 for advanced gastric cancer. METHODS 122 cases of advanced gastric cancer were randomly allocated intogroup VLF (VM26. Leucovorin. 5-FU) and group VF (VM26. 5-FU). and the efficacy and adverse effects of theseregimens were observed respectively. RESULTS There were 6 CR and 34 PR in group VLF. the response ratewas 46%, while 2 CR and 9 PR in group VF, the response rate was 31. 4%, no significant difference was foundbetween the two groups. Although the difference was not significant, the response rate of 51. 6% in the patientswho received 3-4 courses was higher than that of 38. 5% in the patients who received 2 courses. The adverse effects including gastrointestinal reaction, such as nausea, vomiting and bone marrow depression etc. were found,but were tolerable. CONCLUSION VM26 was effective in the treatment of advanced gastric cancer.